Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Solid tumors are generally characterized by an acidic tumor microenvironment (TME) that favors cancer progression, therapy resistance and immune evasion. By single-cell RNA-sequencing analysis in individuals with pancreatic ductal adenocarcinoma (PDAC), we reveal solute carrier family 4 member 4 (SLC4A4) as the most abundant bicarbonate transporter, predominantly expressed by epithelial ductal cells. Functionally, SLC4A4 inhibition in PDAC cancer cells mitigates the acidosis of the TME due to bicarbonate accumulation in the extracellular space and a decrease in lactate production by cancer cells as the result of reduced glycolysis. In PDAC-bearing mice, genetic or pharmacological SLC4A4 targeting improves T cell-mediated immune response and breaches macrophage-mediated immunosuppression, thus inhibiting tumor growth and metastases. In addition,Slc4a4 targeting in combination with immune checkpoint blockade is able to overcome immunotherapy resistance and prolong survival. Overall, our data propose SLC4A4 as a therapeutic target to unleash an antitumor immune response in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 2×
“These effects can be attributed to lactate-mediated impairment of JAK3/STAT5 and MAPK phosphorylation required for a proper response to T cell antigen receptor stimulation 7,52 .”
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 1×
“…occur in 90% of human PDAC, but they are characterized by a loss-of-function mutation in the Smad4 gene occurring in 50% of human pancreatic cancers 22 ; moreover, this cell line is derived from a methylcholanthrene-induced adenocarcinoma, resulting in many more mutations and neoantigens than…”
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Peng, J., Sun, B.-F., Chen, C.-Y., Zhou, J.-Y., Chen, Y.-S., Chen, H., Liu, L., Huang, D., Jiang, J., Cui, G.-S., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0195-y · Cited by 1,321
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Cited by
SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer
Chen, H.-J., Yu, M.-M., Huang, J.-C., Lan, F.-Y., Liao, H.-H., Xu, Z.-H., Yu, Y.-J., Huang, Y.-C., & Chen, F. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217070 · Cited by 35
Potential Theranostic Roles of SLC4 Molecules in Human Diseases
Zhong, J., Dong, J., Ruan, W., & Duan, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015166 · Cited by 16
“SLC4A4 can be a therapeutic target to tackle immunotherapy resistance and prolong survival in PDAC [154].”
BackgroundShi, X., Hu, L., Huang, Y., Zhang, M.-F., Ying, X., Yuan, X., Wen, N., Lu, J., Zou, H., Tan, X., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.014 · Cited by 6
Metadata
- Authors
- Cappellesso, F., Orban, M.-P., Shirgaonkar, N., Berardi, E., Serneels, J., Neveu, M.-A., Di Molfetta, D., Piccapane, F., Caroppo, R., Debellis, L., Ostyn, T., Joudiou, N., Mignion, L., Richiardone, E., Jordan, B. F., Gallez, B., Corbet, C., Roskams, T., DasGupta, R., Tejpar, S., Di Matteo, M., Taverna, D., Reshkin, S. J., Topal, B., Virga, F., & Mazzone, M.
- Venue
- Nature Cancer
- Published
- 2022-12-15
- Volume
- 3
- Issue
- 12
- Pages
- 1464-1483
- ISSN
- 2662-1347 (ISSN-L)
- OpenAlex
- W4311748741
- Cited by
- 134
- References
- 17
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s43018-022-00470-2
- The paper
- Cappellesso, F., Orban, M.-P., Shirgaonkar, N., Berardi, E., Serneels, J., Neveu, M.-A., Di Molfetta, D., Piccapane, F., Caroppo, R., Debellis, L., Ostyn, T., Joudiou, N., Mignion, L., Richiardone, E., Jordan, B. F., Gallez, B., Corbet, C., Roskams, T., DasGupta, R., . . . Mazzone, M. (2022). Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nature Cancer. https://doi.org/10.1038/s43018-022-00470-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.